Accenture (ACN) Q1 2026 earnings review
GenAI Accelerates, But Guidance Remains Conservative
Accenture delivered a clean beat in Q1, with revenue growing 5% in local currency (top of guidance) and adjusted EPS rising 10%. The headline story is the rapid acceleration of GenAI bookings, which hit a record $2.2 billion. However, the macro environment remains bifurcated: Financial Services has roared back to life (+12% growth), while Health & Public Service remains in contraction (-1%) due to U.S. Federal headwinds. Despite the beat, management maintained full-year revenue guidance at 2-5%, implying a cautious outlook for the remainder of FY26.
🐂 Bull Case
GenAI bookings accelerated to $2.2 billion in Q1, up from $1.8 billion in 25Q4. This indicates Accenture is successfully converting pilot interest into large-scale implementation work.
After struggling in FY24, the Financial Services segment has become a growth engine again, posting 12% growth in local currency. This suggests improved discretionary spend in the banking sector.
🐻 Bear Case
Consulting revenue grew only 3% compared to 7% for Managed Services. Clients continue to favor cost-saving outsourcing deals over discretionary strategy work.
Health & Public Service revenue contracted 1% in local currency. Management explicitly flagged an estimated 1% impact from the U.S. federal business on full-year results, signaling ongoing procurement delays.
⚖️ Verdict: 🟢
Positive. The acceleration in total bookings (+10%) and the explosion in GenAI demand outweigh the weakness in the Federal sector. Margin expansion (Adjusted +30bps) confirms strong execution despite optimization costs.
Key Themes
Advanced AI Acceleration
GenAI is no longer just a narrative; it is a material revenue driver. New bookings for Advanced AI reached $2.2 billion in Q1. Tracing the trajectory shows clear acceleration: $1.2B (25Q1) -> $1.4B (25Q2) -> $1.5B (25Q3) -> $1.8B (25Q4) -> $2.2B (26Q1).
Financial Services Recovery
Accelerating. Financial Services has swung from a laggard to a leader. Revenue grew 12% in local currency in Q1, continuing the momentum from late FY25. This 12% growth significantly outpaces the company average of 5%, suggesting a major thawing in bank IT budgets.
Health & Public Service Contraction
Reversing. Once a stalwart defender during macro weakness, Health & Public Service has turned negative, shrinking 1% in local currency in Q1. This validates management's prior warnings about US Federal procurement delays. The segment has decelerated from +12% growth in 25Q1 to -1% in 26Q1.
Margin Expansion via Optimization
Stable/Improving. Despite GAAP margins falling due to $308M in optimization costs, Adjusted Operating Margin expanded 30bps to 17.0%. Management raised the floor of their full-year margin guidance (now 15.7-15.9%), indicating confidence that these efficiency measures are structurally improving profitability.
Other KPIs
Accelerating. Adjusted EPS grew 10% YoY, outpacing revenue growth of 6% USD. This demonstrates strong leverage from margin expansion and share repurchases ($2.3B in Q1).
Stable. Up significantly from $0.9B in 25Q1. Operating cash flow of $1.66B shows strong conversion. The company maintains its FY26 FCF guidance of $9.8-$10.5B.
Stable. Grew 7% in local currency (vs 3% for Consulting). Managed Services continues to provide the floor for growth, representing nearly 50% of total revenue.
Guidance
Decelerating. The guidance implies 1% to 5% growth in local currency. The midpoint (3%) is below Q1's actual 5% growth, suggesting management sees potential seasonal softness or continued federal drag.
Stable. Management reiterated the full-year range despite the Q1 beat. They noted that excluding the ~1% impact from the U.S. federal business, growth would be 3-6%.
Stable. Represents 5% to 8% growth. The range remains unchanged from the prior quarter, reinforcing the theme of prudent conservatism.
Key Questions
Federal Headwinds Duration
Health & Public Service turned negative (-1%) this quarter. Do you expect the U.S. Federal drag to persist throughout the entirety of FY26, or is there a specific quarter where comps ease?
Consulting vs. GenAI Conversion
With GenAI bookings accelerating to $2.2B, why is Consulting revenue growth still muted at 3%? Is GenAI work cannibalizing legacy consulting projects, or is the lag from booking to revenue recognition longer than traditional work?
Margin Expansion Drivers
Adjusted margins expanded 30bps. How much of this is driven by the specific 'Business Optimization' cost actions versus pricing power or mix shift toward higher-margin Managed Services?
Q2 Deceleration Implication
The Q2 revenue guidance midpoint implies ~3% growth, a deceleration from Q1's 5%. Is this purely conservatism regarding the macro environment, or are there specific project completions/cancellations expected in Q2?